ANXA1 and neoplasm: From a therapeutic standpoint, the use of an ANXA1-derived 11 amino acid–long peptide (named A11) which occupies the ANXA1-binding site on EphA2, preventing its binding to EphA2, increased c-Cbl interaction with EphA2, receptor ubiquitination, and degradation, thereby inhibiting in vitro cell growth, migration, and invasion, as well as in vivo tumor growth [57].